Angion Biomedica Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Uniondale, n.y., oct. 18, 2021 (globe newswire) -- angion biomedica corp (nasdaq:angn), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the american society of nephrology's kidney week 2021 virtual meeting to be held november 4-7, 2021.

Uniondale, n.y., sept. 08, 2021 (globe newswire) -- angion biomedica corp. (nasdaq:angn), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ang-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am edt on monday, september 20th.

Uniondale, n.y., sept. 02, 2021 (globe newswire) -- angion biomedica corp (nasdaq:angn), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the h.c. wainwright 23rd annual global investment conference and participate in a fireside chat with oppenheimer senior biotech analyst justin kim at the oppenheimer fall healthcare life sciences & medtech summit.

Uniondale, n.y., aug. 03, 2021 (globe newswire) -- angion biomedica corp (nasdaq:angn), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced positive results from its phase 1 study in healthy volunteers for ang-3070, a novel oral tyrosine kinase receptor inhibitor (tki) being developed for the treatment of fibrotic diseases. angion also announced the fda's acceptance of an ind application supporting the initiation of a phase 2 trial in patients with primary proteinuric kidney diseases in 2021. additionally, the company announced it will host a virtual fibrosis r&d day on september 20, 2021.

Uniondale, n.y., june 29, 2021 (globe newswire) -- angion biomedica corp. (nasdaq:angn), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced that its exploratory phase 2 ali-201 trial of ang-3777 in patients with severe covid-19 related pneumonia at high risk for acute respiratory distress syndrome (ards) did not meet the primary or secondary efficacy endpoints. the adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe covid-19 pneumonia.

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

PHX, BEPC, ANGN, CXM and GMBL have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2022.

Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.  The trial began enrolling.

Here's what you need to know about trading penny stocks on June 1st The post What to Know About Buying Penny Stocks on June 1st appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the American Society of Nephrology's Kidney Week 2021 virtual meeting to be held November 4-7, 2021.

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th.

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.